Group 1 - NetEase-S (09999) rose over 6.5% after the announcement of the anniversary version of "Yanyun Sixteen Sounds" launching on December 27, 2025, which topped the iOS game sales chart. Huatai Securities previously indicated that the first-year revenue could reach 20-30 billion [1] - Commercial aerospace concept stocks surged, with Asia Pacific Satellite (01045) up 31.29%, Aerospace Holdings (00031) up 20%, and Goldwind Technology (02208) up 18.27%. Blue Arrow Aerospace's IPO application was accepted, marking it as the first company to be accepted under the new listing standards since the expansion [1] - Li Auto-W (02015) increased over 5.6% after reporting 44,246 vehicle deliveries in December 2025, totaling 109,194 for Q4. By December 31, 2025, cumulative deliveries reached 1,540,215, making it the first new force brand to achieve the 1.5 million delivery milestone [1] Group 2 - Hua Hong Semiconductor (01347) surged over 11% after announcing plans to acquire 97.4988% of Huali Micro's shares and raise funds through a stock issuance to specific investors [2] - Skyworth Group (00751) rose over 10% following the signing of a 10MW distributed photovoltaic power station project in Italy, marking a significant step in its overseas market expansion [2] - Baidu Group-SW (09888) increased over 8.1%, with a cumulative rise of over 15% this week, after announcing the submission of a listing application for Kunlun Chip on the Hong Kong Stock Exchange [2] Group 3 - SaaS concept stocks saw significant gains, with Lion Holding (02562) up 16.48%, Kingdee International (00268) up 7.22%, and Huily Technology (01860) up 4.52%. Meta announced a multi-billion dollar acquisition of the AI product developer Manus [3] - Xirui (02507) rose nearly 10% following the release of the U.S. Department of Transportation's strategic plans aimed at advancing the future of aviation [3] Group 4 - Meitu Company (01357) increased over 5.7% after announcing a $250 million convertible bond issuance to Alibaba, which could result in Alibaba holding 6.82% of Meitu's shares, making it the third-largest shareholder [4] Group 5 - Bitcoin surpassed $88,000, leading to a rise in some cryptocurrency mining stocks, including TeraWulf (WULF.US) up 3.05% and Applied Digital (APLD.US) up 1.83% [5] - Mindonghong (ORIS.US) surged 22.13% after signing a non-binding letter of intent to acquire Hubei Daguan Tea Industry Group, aiming to strengthen upstream supply control [5] - Wanda Biopharmaceuticals (VNDA.US) rose 25.46% after announcing FDA approval for its new drug Nereus, intended for preventing exercise-induced vomiting [5] Group 6 - Storage concept stocks fell, with SanDisk (SNDK.US) down 1.18%, Western Digital (WDC.US) down 2.15%, and Micron Technology (MU.US) down 2.47% [6] - Corcep Medical (CORT.US) plummeted 50.42% after receiving a complete response letter from the FDA regarding its new drug application for Relacorilant [6] - TSMC (TSM.US) rose 1.44% as Nvidia is negotiating new orders for its H200 chip, with TSMC expected to expand capacity by Q2 2026 [6] Group 7 - New energy vehicle stocks declined, with Tesla (TSLA.US) down 1.04%, NIO (NIO.US) down 7.27%, and Li Auto (LI.US) down 1.97% [7] - Pony.ai (PONY.US) fell 0.96% despite announcing that its Robotaxi fleet exceeded 1,159 vehicles, surpassing its 1,000 vehicle target for 2025 [7]

Core Viewpoint - B. Riley has raised the price target for Vanda Pharmaceuticals (VNDA) to $14 from $11, maintaining a Buy rating, following the FDA's approval of Nereus for motion sickness-induced vomiting prevention, indicating a positive outlook for the company as it is seen as an "ongoing turnaround story" [1] Summary by Category Company Performance - The FDA approval of Nereus is expected to unlock over $100 million in peak revenue for Vanda Pharmaceuticals [1] - The approval is also significant for the potential approval of tradipitant, which is related to GLP-1 induced nausea [1] Market Position - Vanda Pharmaceuticals is currently trading at an "excessive discount" as it approaches two more potential approvals within the next 12 months [1]

Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) stock price increased by over 25.46% following the FDA approval of its new drug Nereus, which is intended for the prevention of vomiting induced by motion [1][2]. Group 1: FDA Approval and Drug Details - The FDA approval of Nereus is based on results from three clinical studies that compared the drug group with a placebo group to assess the occurrence of vomiting [2]. - Data from the trials indicated that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [2]. Group 2: Market Implications - The approval of Nereus is expected to provide a new commercialization growth point for the company and further enrich its product portfolio in the central nervous system and related indications [2].

Craft Beer Industry Outlook - The craft beer industry is experiencing a shakeout phase that began in 2023, with brewery closures outpacing openings for the third consecutive year, including notable closures like Rogue Ales & Spirits and Iron Hill Brewery in 2025 [5] - Analysts highlight pressures such as higher commodity and labor costs, slowing taproom traffic, increased competition from other alcohol formats, and regulatory challenges, leading to a decline in beer consumption frequency among drinkers [6] - The Brewers Association's economist describes the industry as being in turbulent waters, with changing consumer habits and inflation impacting performance, but notes that brewers are adapting their offerings and business models [7] Future Projections - The outlook for 2026 indicates another small volume decline, continued closures, and consolidation, but a gradual stabilization as weaker players exit and stronger, taproom-centric breweries adjust to new consumer tastes [7] - There are cautious reasons for optimism, including falling interest rates, potential legal clarity on tariffs, and consumer surveys indicating a desire to socialize more, which could positively impact sales [8] Company Developments - Tilray has emerged as a significant player in the craft beer sector after acquiring multiple brands from Anheuser-Busch InBev and Molson Coors, while Boston Beer remains a key name despite diversifying its portfolio [9] - Nike's CEO recently purchased over $1 million in shares, making it the biggest gainer in the S&P [9] Economic Indicators - Weekly initial jobless claims fell by 16,000 to 199,000, below the consensus of 219,000, with continuing claims also declining to 1.866 million [11]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 100 points, down 0.28% to 48,229.87, NASDAQ down 0.26% to 23,359.33, and S&P 500 down 0.26% to 6,878.07 [1] - European shares were also lower, with the eurozone's STOXX 600 slipping 0.14%, Spain's IBEX 35 Index down 0.27%, London's FTSE 100 down 0.09%, and France's CAC 40 down 0.23% [6] - Asian markets closed mixed, with Hong Kong's Hang Seng Index falling 0.87%, China's Shanghai Composite gaining 0.09%, and India's BSE Sensex gaining 0.64% [7] Commodities - Oil traded up 0.1% to $58.02, while gold traded down 0.8% at $4,351.00, silver down 7.3% to $72.255, and copper fell 1.9% to $5.6710 [5] Company News - Anghami Inc. shares surged 50% to $3.7306 after reporting a year-over-year increase in H1 results [9] - Vanda Pharmaceuticals Inc. shares rose 32% to $9.28 following FDA approval of NEREUS for motion-induced vomiting prevention [9] - Intelligent Bio Solutions Inc. shares increased 102% to $8.27 after announcing a strategic manufacturing partnership with Syrma Johari MedTech [9] - Corcept Therapeutics Incorporated shares dropped 52% to $34.04 after receiving a Complete Response Letter from the FDA for Relacorilant [9] - FuelCell Energy, Inc. shares fell 10% to $7.18 after filing for an amended common stock offering [9] - SMX (Security Matters) Public Limited Company shares decreased 37% to $32.30 [9] Economic Indicators - U.S. initial jobless claims declined by 16,000 to 199,000, compared to market estimates of 220,000 [10] - U.S. crude oil inventories, excluding the Strategic Petroleum Reserve, dipped by 1.934 million barrels, marking the largest weekly decline since mid-November, against market estimates of a 0.9 million-barrel fall [2][10]

Summary of Key Points Core Viewpoint - FuelCell Energy, Inc. (NASDAQ:FCEL) experienced a significant decline in share price following the announcement of an amended common stock offering, which allows the company to sell up to $200 million in shares [1]. Company Specifics - FuelCell Energy shares dropped by 8.9%, closing at $7.23 after the announcement of the amended sales agreement [1]. - Intelligent Bio Solutions Inc. (NASDAQ:INBS) saw a remarkable increase of 107% in share price, reaching $8.51, due to a strategic manufacturing partnership with Syrma Johari MedTech [4]. - ESH Acquisition Corp. (NASDAQ:ESHA) gained 59% to $22.86, while Northann Corp. (NYSE:NCL) rose by 58.2% to $0.3071 [4]. - Aimei Health Technology Co., Ltd (NASDAQ:AFJK) shares surged by 50.3% to $127.00 [4]. - Anghami Inc. (NASDAQ:ANGH) reported a year-over-year increase in H1 results, leading to a 44.6% rise in share price to $3.6000 [4]. - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares increased by 33.1% to $9.36 after receiving FDA approval for NEREUS [4]. - Datavault AI Inc. (NASDAQ:DVLT) gained 32% to $0.6802, while Oriental Rise Holdings Limited (NASDAQ:ORIS) jumped 31% to $1.6001 following a non-binding letter of intent to acquire Hubei Daguan Tea Industry Group [4]. - Urgent.ly Inc. (NASDAQ:ULY) rose 31% to $3.6000 after adjourning its annual stockholder meeting due to insufficient votes [4]. - Momentus Inc. (NASDAQ:MNTS) gained 26.4% to $6.53, and Axsome Therapeutics, Inc. (NASDAQ:AXSM) rose 16.1% to $172.90 after announcing plans to file a new drug application [4]. Market Movements - Corcept Therapeutics Incorporated (NASDAQ:CORT) saw a significant decline of 50.8% to $34.51 after receiving a Complete Response Letter from the FDA [4]. - SMX (Security Matters) Public Limited Company (NASDAQ:SMX) fell 39.2% to $31.30, while Delixy Holdings Limited (NASDAQ:DLXY) dipped 37.2% to $0.8853 [4]. - MultiSensor AI Holdings, Inc. (NASDAQ:MSAI) declined by 30.7% to $0.2831, and Profusa, Inc. (NASDAQ:PFSA) fell 21.3% to $0.0958 after announcing a new distributor partnership in France [4]. - NIO Inc. (NYSE:NIO) experienced a drop of 9.2% to $4.9950, and Wheels Up Experience Inc. (NYSE:UP) fell 6.3% to $0.5844 [4].

Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) shares surged over 32% to $9.33 following FDA approval of its new drug Nereus, aimed at preventing exercise-induced vomiting [1] Group 1: FDA Approval and Drug Details - The FDA's approval of Nereus is based on results from three clinical studies comparing the drug to a placebo in terms of vomiting occurrence [1] - Data indicates that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [1] Group 2: Market Implications - The approval of Nereus is expected to provide a new commercial growth opportunity for the company and enhance its product portfolio in the central nervous system and related indications [1]

Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) shares surged over 32% to $9.33 following FDA approval of its new drug Nereus, aimed at preventing exercise-induced vomiting [1] Group 1: FDA Approval and Drug Details - The FDA approval of Nereus is based on results from three clinical studies comparing the drug group to a placebo group to assess vomiting occurrences [1] - Data indicates that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [1] Group 2: Market Implications - The approval is expected to provide a new commercialization growth point for the company and enhance its product portfolio in the central nervous system and related indications [1]

Core Insights - U.S. stocks experienced a decline, with the Dow Jones index dropping over 100 points on Wednesday [1] Group 1: Axsome Therapeutics - Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares surged 16.1% to $172.90 after announcing plans to file a new drug application for AXS-12 in January following FDA feedback [1] - The FDA granted Priority Review to Axsome's AXS-05 for Alzheimer's Agitation [1] Group 2: Other Notable Stock Movements - Aimei Health Technology Co., Ltd (NASDAQ:AFJK) shares increased by 50.3% to $127.00 [3] - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) saw a gain of 34.4% to $9.45 after receiving FDA approval for NEREUS, aimed at preventing motion-induced vomiting [3] - Jyong Biotech Ltd. (NASDAQ:MENS) rose 11.8% to $4.7107 [3] - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) increased by 7.5% to $3.5598 [3] - Empresa Distribuidora y Comercializadora Norte Sociedad Anónima (NYSE:EDN) rose 6% to $31.93 [3] - mF International Limited (NASDAQ:MFI) gained 4.8% to $19.46 [3] - Plug Power Inc. (NASDAQ:PLUG) increased by 4.1% to $2.0150, with Clear Street analyst Tim Moore upgrading the stock from Hold to Buy and lowering the price target from $3.5 to $3 [3]

Core Viewpoint - Vanda Pharmaceuticals' stock surged over 26% to $8.9 following the FDA approval of its drug for preventing exercise-induced nausea, marking the first such approval in over 40 years [1] Company Summary - Vanda Pharmaceuticals announced the FDA approval of its drug named Nereus, which is designed to prevent exercise-induced vomiting [1] - The company plans to launch Nereus in the coming months [1] Industry Summary - The approval of Nereus represents a significant milestone in the pharmaceutical industry, as it is the first drug of its kind approved in over four decades [1]